PandemieGrippaleV1, Main, Exploration, bibRecord, 001864

Effectiveness of Monovalent 2009 Pandemic Influenza A Virus Subtype H1N1 and 2010- 2011 Trivalent Inactivated Influenza Vaccines in Wisconsin During the 2010-2011 Influenza Season

Identifieur interne : 001864 ( Main/Exploration ); précédent : 001863; suivant : 001865

Effectiveness of Monovalent 2009 Pandemic Influenza A Virus Subtype H1N1 and 2010- 2011 Trivalent Inactivated Influenza Vaccines in Wisconsin During the 2010-2011 Influenza Season

Auteurs : Allen C. Bateman [États-Unis] ; Burney A. Kieke [États-Unis] ; Stephanie A. Irving [États-Unis] ; Jennifer K. Meece [États-Unis] ; David K. Shay [Géorgie] ; Edward A. Belongia [États-Unis]

Source :

The Journal of infectious diseases [ 0022-1899 ] ; 2013.

RBID : Pascal:13-0149663

Descripteurs français

Pascal (Inist)
- Soustype, Souche inactivée, Wisconsin, Infection, Grippe, Virus grippal A(H1N1).

English descriptors

KwdEn :
- Inactivated strain, Infection, Influenza, Influenzavirus A(H1N1), Subtype, Wisconsin.

Abstract

Background. The 2009 influenza A virus subtype H1N1 (A[H1N1]pdm09) did not exhibit antigenic drift during the 2010-2011 influenza season, providing an opportunity to investigate the duration of protection after vaccination. We estimated the independent effects of 2010-2011 seasonal trivalent inactivated influenza vaccine (TIV) and A (H1N1)pdm09 vaccine for preventing medically attended influenza A virus infection during the 2010-2011 season. Methods. Individuals were tested for influenza A virus by real-time reverse transcription polymerase chain reaction (rRT-PCR) after a clinical encounter for acute respiratory illness. Case-control analyses compared participants with rRT-PCR-confirmed influenza A virus infection and test-negative controls. Vaccine effectiveness was estimated separately for monovalent pandemic vaccine and TIV and was calculated as 100 x [ 1 - adjusted odds ratio], where the odds ratio was adjusted for potential confounders. Results. The effectiveness of TIV against influenza A virus infection was 63% (95% confidence interval [CI], 37%-78%). The effectiveness of TIV against A(H1N1)pdm09 infection was 77% (95% CI, 44%-90%). Monovalent vaccine administered between October 2009 and April 2010 was not protective during the 2010-2011 season, with an effectiveness of -1% (95% CI, -146% to 59%) against A(H1N1)pdm09 infection. Conclusions. Monovalent vaccine provided no sustained protection against A(H1N1)pdm09 infection during the 2010-2011 season. This waning effectiveness supports the need for annual revaccination, even in the absence of antigenic drift in A(H1N1)pdm09.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000319
to stream PascalFrancis, to step Curation: 001B07
to stream PascalFrancis, to step Checkpoint: 000295
to stream Main, to step Merge: 001892
to stream Main, to step Curation: 001864

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Effectiveness of Monovalent 2009 Pandemic Influenza A Virus Subtype H1N1 and 2010- 2011 Trivalent Inactivated Influenza Vaccines in Wisconsin During the 2010-2011 Influenza Season</title>
<author><name sortKey="Bateman, Allen C" sort="Bateman, Allen C" uniqKey="Bateman A" first="Allen C." last="Bateman">Allen C. Bateman</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Marshfield Clinic Research Foundation</s1>
<s2>Marshfield, Wisconsin</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kieke, Burney A" sort="Kieke, Burney A" uniqKey="Kieke B" first="Burney A." last="Kieke">Burney A. Kieke</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Marshfield Clinic Research Foundation</s1>
<s2>Marshfield, Wisconsin</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Irving, Stephanie A" sort="Irving, Stephanie A" uniqKey="Irving S" first="Stephanie A." last="Irving">Stephanie A. Irving</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Marshfield Clinic Research Foundation</s1>
<s2>Marshfield, Wisconsin</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Meece, Jennifer K" sort="Meece, Jennifer K" uniqKey="Meece J" first="Jennifer K." last="Meece">Jennifer K. Meece</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Marshfield Clinic Research Foundation</s1>
<s2>Marshfield, Wisconsin</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shay, David K" sort="Shay, David K" uniqKey="Shay D" first="David K." last="Shay">David K. Shay</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Influenza Division, Centers for Disease Control and Prevention</s1>
<s2>Atlanta</s2>
<s3>GEO</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Géorgie</country>
<wicri:noRegion>Atlanta</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Belongia, Edward A" sort="Belongia, Edward A" uniqKey="Belongia E" first="Edward A." last="Belongia">Edward A. Belongia</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Marshfield Clinic Research Foundation</s1>
<s2>Marshfield, Wisconsin</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">13-0149663</idno>
<date when="2013">2013</date>
<idno type="stanalyst">PASCAL 13-0149663 INIST</idno>
<idno type="RBID">Pascal:13-0149663</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000319</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001B07</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000295</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000295</idno>
<idno type="wicri:doubleKey">0022-1899:2013:Bateman A:effectiveness:of:monovalent</idno>
<idno type="wicri:Area/Main/Merge">001892</idno>
<idno type="wicri:Area/Main/Curation">001864</idno>
<idno type="wicri:Area/Main/Exploration">001864</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Effectiveness of Monovalent 2009 Pandemic Influenza A Virus Subtype H1N1 and 2010- 2011 Trivalent Inactivated Influenza Vaccines in Wisconsin During the 2010-2011 Influenza Season</title>
<author><name sortKey="Bateman, Allen C" sort="Bateman, Allen C" uniqKey="Bateman A" first="Allen C." last="Bateman">Allen C. Bateman</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Marshfield Clinic Research Foundation</s1>
<s2>Marshfield, Wisconsin</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kieke, Burney A" sort="Kieke, Burney A" uniqKey="Kieke B" first="Burney A." last="Kieke">Burney A. Kieke</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Marshfield Clinic Research Foundation</s1>
<s2>Marshfield, Wisconsin</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Irving, Stephanie A" sort="Irving, Stephanie A" uniqKey="Irving S" first="Stephanie A." last="Irving">Stephanie A. Irving</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Marshfield Clinic Research Foundation</s1>
<s2>Marshfield, Wisconsin</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Meece, Jennifer K" sort="Meece, Jennifer K" uniqKey="Meece J" first="Jennifer K." last="Meece">Jennifer K. Meece</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Marshfield Clinic Research Foundation</s1>
<s2>Marshfield, Wisconsin</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shay, David K" sort="Shay, David K" uniqKey="Shay D" first="David K." last="Shay">David K. Shay</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Influenza Division, Centers for Disease Control and Prevention</s1>
<s2>Atlanta</s2>
<s3>GEO</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Géorgie</country>
<wicri:noRegion>Atlanta</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Belongia, Edward A" sort="Belongia, Edward A" uniqKey="Belongia E" first="Edward A." last="Belongia">Edward A. Belongia</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Marshfield Clinic Research Foundation</s1>
<s2>Marshfield, Wisconsin</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">The Journal of infectious diseases</title>
<title level="j" type="abbreviated">J. infect. dis.</title>
<idno type="ISSN">0022-1899</idno>
<imprint><date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">The Journal of infectious diseases</title>
<title level="j" type="abbreviated">J. infect. dis.</title>
<idno type="ISSN">0022-1899</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Inactivated strain</term>
<term>Infection</term>
<term>Influenza</term>
<term>Influenzavirus A(H1N1)</term>
<term>Subtype</term>
<term>Wisconsin</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Soustype</term>
<term>Souche inactivée</term>
<term>Wisconsin</term>
<term>Infection</term>
<term>Grippe</term>
<term>Virus grippal A(H1N1)</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background. The 2009 influenza A virus subtype H1N1 (A[H1N1]pdm09) did not exhibit antigenic drift during the 2010-2011 influenza season, providing an opportunity to investigate the duration of protection after vaccination. We estimated the independent effects of 2010-2011 seasonal trivalent inactivated influenza vaccine (TIV) and A (H1N1)pdm09 vaccine for preventing medically attended influenza A virus infection during the 2010-2011 season. Methods. Individuals were tested for influenza A virus by real-time reverse transcription polymerase chain reaction (rRT-PCR) after a clinical encounter for acute respiratory illness. Case-control analyses compared participants with rRT-PCR-confirmed influenza A virus infection and test-negative controls. Vaccine effectiveness was estimated separately for monovalent pandemic vaccine and TIV and was calculated as 100 x [ 1 - adjusted odds ratio], where the odds ratio was adjusted for potential confounders. Results. The effectiveness of TIV against influenza A virus infection was 63% (95% confidence interval [CI], 37%-78%). The effectiveness of TIV against A(H1N1)pdm09 infection was 77% (95% CI, 44%-90%). Monovalent vaccine administered between October 2009 and April 2010 was not protective during the 2010-2011 season, with an effectiveness of -1% (95% CI, -146% to 59%) against A(H1N1)pdm09 infection. Conclusions. Monovalent vaccine provided no sustained protection against A(H1N1)pdm09 infection during the 2010-2011 season. This waning effectiveness supports the need for annual revaccination, even in the absence of antigenic drift in A(H1N1)pdm09.</div>
</front>
</TEI>
<affiliations><list><country><li>Géorgie</li>
<li>États-Unis</li>
</country>
<region><li>Wisconsin</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Wisconsin"><name sortKey="Bateman, Allen C" sort="Bateman, Allen C" uniqKey="Bateman A" first="Allen C." last="Bateman">Allen C. Bateman</name>
</region>
<name sortKey="Belongia, Edward A" sort="Belongia, Edward A" uniqKey="Belongia E" first="Edward A." last="Belongia">Edward A. Belongia</name>
<name sortKey="Irving, Stephanie A" sort="Irving, Stephanie A" uniqKey="Irving S" first="Stephanie A." last="Irving">Stephanie A. Irving</name>
<name sortKey="Kieke, Burney A" sort="Kieke, Burney A" uniqKey="Kieke B" first="Burney A." last="Kieke">Burney A. Kieke</name>
<name sortKey="Meece, Jennifer K" sort="Meece, Jennifer K" uniqKey="Meece J" first="Jennifer K." last="Meece">Jennifer K. Meece</name>
</country>
<country name="Géorgie"><noRegion><name sortKey="Shay, David K" sort="Shay, David K" uniqKey="Shay D" first="David K." last="Shay">David K. Shay</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001864 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001864 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    PandemieGrippaleV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:13-0149663
   |texte=   Effectiveness of Monovalent 2009 Pandemic Influenza A Virus Subtype H1N1 and 2010- 2011 Trivalent Inactivated Influenza Vaccines in Wisconsin During the 2010-2011 Influenza Season
}}

This area was generated with Dilib version V0.6.34.
Data generation: Wed Jun 10 11:04:28 2020. Site generation: Sun Mar 28 09:10:28 2021

	Serveur d'exploration sur les pandémies grippales
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les pandémies grippales

Effectiveness of Monovalent 2009 Pandemic Influenza A Virus Subtype H1N1 and 2010- 2011 Trivalent Inactivated Influenza Vaccines in Wisconsin During the 2010-2011 Influenza Season

Effectiveness of Monovalent 2009 Pandemic Influenza A Virus Subtype H1N1 and 2010- 2011 Trivalent Inactivated Influenza Vaccines in Wisconsin During the 2010-2011 Influenza Season

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri